AF
RVLP

Allworth Financial’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Allworth Financial’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-75
Closed – – 3207
2022
Q2 		$0 Buy
+75
New +$109 ﹤0.01% 2930

Other funds holding RVLP

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
RA
Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Allworth Financial's RVLP Position: Q3 2022 in Review

Allworth Financial sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q3 2022, closing a stake of 75 shares.

Allworth Financial first reported a position in RVLP in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 46 funds tracked by Wall St. Rank hold RVLP as of Q3 2022.

  • Allworth Financial reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Allworth Financial sold 75 RVL Pharmaceuticals plc Ordinary Shares shares in Q3 2022.
  • Allworth Financial first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q2 2022 and held it in 1 quarter.
  • Allworth Financial's RVL Pharmaceuticals plc Ordinary Shares position peaked at $0 in Q2 2022.
  • 46 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q3 2022.

Based on Allworth Financial's 13F filing for Q3 2022, filed 18 Oct 2022.